Clinical Trial Update: Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I) [Phase 3]

View source ↗

Summary

Phase 3 ODYSSEY COMBO I evaluated alirocumab on top of lipid-modifying therapy in high-risk hypercholesterolemia; efficacy and safety results were posted in 201…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypercholesterolemia

Drugs mentioned

• Praluent (alirocumab)

Snippet

Sponsor: Sanofi | Conditions: Hypercholesterolemia | Phase 3 | Status: COMPLETED | Results posted: 2015-11-06